Quest Diagnostics Stock

Quest Diagnostics FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Quest Diagnostics (DGX) as of Aug 22, 2026 is 137.00 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 104.36 % — a change of 31.27% (higher).

FCF Conversion

137.00 %

YoY

31.27%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Quest Diagnostics is 2026 137.00 % . FCF Conversion Rate (FCF/EBITDA) of Quest Diagnostics was 2025 104.36 % . It decreases by 31.27% higher compared to the previous year.

The Quest Diagnostics FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
111.01 USD
Jan 1, 2019
98.25 USD
Jan 1, 2020
110.90 USD
Jan 1, 2021
91.73 USD
Jan 1, 2022
138.90 USD
Jan 1, 2023
101.17 USD
Jan 1, 2024
104.36 USD
Jan 1, 2025
137.00 USD
The Quest Diagnostics FCF Conversion history
YEARFCF ConversionYoY
137.00 %+31.27%
104.36 %+3.15%
101.17 %-27.16%
138.90 %+51.42%
91.73 %-17.29%
110.90 %+12.87%
98.25 %-11.49%
111.01 %-7.15%
119.56 %-0.62%
120.31 %+55.94%
77.15 %-31.91%
113.31 %
Access this data via the Eulerpool API

Quest Diagnostics Stock analysis

What does Quest Diagnostics do? Quest Diagnostics Inc is a leading company in the field of diagnostic information and services, headquartered in New Jersey, USA. The company is dedicated to providing medical professionals and patients worldwide with fast, accurate, and preventive diagnostic tests. The history of Quest Diagnostics dates back to 1967 when the company MetPath was founded by Dr. Paul A. Brown. In the following years, several acquisitions and mergers took place, eventually leading to the establishment of Quest Diagnostics in 1996. Since then, the company has continuously evolved and now offers a wide range of diagnostic tests and services, ranging from the analysis of blood samples to genetic testing procedures. The business model of Quest Diagnostics is based on providing high-quality and individualized information to medical professionals and patients to assist in the diagnosis, treatment, and cure of their health problems. The company works closely with doctors, hospitals, and other medical institutions worldwide to offer a comprehensive range of innovative diagnostic products, procedures, and technologies tailored to meet specific needs. Quest Diagnostics offers a wide range of services, ranging from laboratory testing to data management and clinical trials. The company has various business segments, including the Diagnostic Services business, the Medical Research Services business, and the Information Services business. In the field of Diagnostic Services, Quest Diagnostics offers a broad spectrum of laboratory tests divided into different categories such as cancer diagnostics, cardiology, endocrinology, immunology, and infectious diseases. The company also provides a variety of genetic tests that enable precise analysis of individual genomes, supporting the diagnosis and treatment of various genetic disorders. In the medical research field, Quest Diagnostics provides a range of services to support clinical trials and drug development. The company also offers a wide range of laboratory tests used in biomedical research to improve people's health and well-being. The Information Services business segment of Quest Diagnostics mainly focuses on providing innovative solutions in the field of data management and information technology. This includes the development of software tools that can be used for the analysis and management of health data. Additionally, the company offers consulting services to help medical professionals address challenges related to information processing and data integration. Quest Diagnostics is a company based on innovation and knowledge that collaborates closely with doctors, clinics, and other medical facilities worldwide to offer a relatively comprehensive range of need-specific diagnostic products, procedures, and solutions. From cancer diagnostics to genomic diagnostics, from clinical trials to information and data services, and a wide range of molecular diagnostic tests and laboratory analyses, Quest Diagnostics provides top-notch solutions for optimal patient care, contributing to the goal of improving global healthcare for people worldwide. Quest Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quest Diagnostics stock

FCF Conversion Rate (FCF/EBITDA) of Quest Diagnostics is 137.00 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Quest Diagnostics changed from 104.36 % to 137.00 %, representing a 31.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Quest Diagnostics since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Quest Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Quest Diagnostics

All Key Metrics — Quest Diagnostics